Mahdi Jalili

Dr. Mahdi Jalili

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
KAKamran Alimoghaddam
Kamran Alimoghaddam
SRShahrbano Rostami
Shahrbano Rostami
SGSeyed H. Ghaffari
Seyed H. Ghaffari
MJMohamad Jahani
Mohamad Jahani
MJMahdi Jalili
Mahdi Jalili
Purpose: The long-term follow-up results of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy show high cure rates. Several studies have shown high efficacy of single-agent arsenic trioxide in newly diagnosed APL. However, long-term follow-up results are needed. Patients and Methods: One hundred ninety-seven patients with newly diagnosed APL were treated with arsenic trioxide 0.15 mg/kg daily intravenous infusion until complete remission (CR). After achieving CR, the patients received one to four more courses of therapy with arsenic trioxide as consolidation and were observed with reverse-transcriptase polymerase chain reaction studies from peripheral blood (to detect of minimal residual disease) every 3 months or until relapse or death. Results: The morphologic CR rate was 85.8%. The most common cause of remission failure was early death owing to APL differentiation syndrome (13.2%). The most important prognostic factor for early mortality was a high WBC count at presentation. The 5-year disease-free survival (DFS) rate was 66.7% ± 4% (SE). Relapse after 5 years in CR was rare. The 5-year overall survival (OS) rate by intention-to-treat analysis was 64.4% ± 4%. In patients who achieved CR, OS and DFS were identical. Conclusion: The long-term follow-up of newly diagnosed patients with APL treated with single-agent arsenic trioxide shows high rates of DFS and OS.

11 July 2011 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
Amir Ali HamidiehAmir Ali Hamidieh
Amir Ali Hamidieh
ZPZ Pourpak
Z Pourpak
MHM Hosseinzadeh
M Hosseinzadeh
MFMohammad Reza Fazlollahi
Mohammad Reza Fazlollahi
KAK Alimoghaddam
K Alimoghaddam
AGA Ghavamzadeh
A Ghavamzadeh

15 July 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
PSPejman Salahshouri
Pejman Salahshouri
MEModjtaba Emadi-Baygi
Modjtaba Emadi-Baygi
MJMahdi Jalili
Mahdi Jalili
FKFaiz Muhammad Khan
Faiz Muhammad Khan
OWOlaf Wolkenhauer
Olaf Wolkenhauer
Ali Salehzadeh-YazdiAli Salehzadeh-Yazdi
Ali Salehzadeh-Yazdi
The human gut microbiota plays a dual key role in maintaining human health or inducing disorders, for example, obesity, type 2 diabetes, and cancers such as colorectal cancer (CRC). High-throughput data analysis, such as metagenomics and metabolomics, have shown the diverse effects of alterations in dynamic bacterial populations on the initiation and progression of colorectal cancer. However, it is well established that microbiome and human cells constantly influence each other, so it is not appropriate to study them independently. Genome-scale metabolic modeling is a well-established mathematical framework that describes the dynamic behavior of these two axes at the system level. In this study, we created community microbiome models of three conditions during colorectal cancer progression, including carcinoma, adenoma and health status, and showed how changes in the microbial population influence intestinal secretions. Conclusively, our findings showed that alterations in the gut microbiome might provoke mutations and transform adenomas into carcinomas. These alterations include the secretion of mutagenic metabolites such as H2S, NO compounds, spermidine and TMA (trimethylamine), as well as the reduction of butyrate. Furthermore, we found that the colorectal cancer microbiome can promote inflammation, cancer progression (e.g., angiogenesis) and cancer prevention (e.g., apoptosis) by increasing and decreasing certain metabolites such as histamine, glutamine and pyruvate. Thus, modulating the gut microbiome could be a promising strategy for the prevention and treatment of CRC.

Verified
Journal Article
Open access
PDF file
MJMahdi Jalili
Mahdi Jalili
Martin ScharmMartin Scharm
Martin Scharm
OWOlaf Wolkenhauer
Olaf Wolkenhauer
MDMehdi Damaghi
Mehdi Damaghi
Ali Salehzadeh-YazdiAli Salehzadeh-Yazdi
Ali Salehzadeh-Yazdi
Metabolic heterogeneity is a hallmark of cancer and can distinguish a normal phenotype from a cancer phenotype. In the systems biology domain, context-specific models facilitate extracting physiologically relevant information from high-quality data. Here, to utilize the heterogeneity of metabolic patterns to discover biomarkers of all cancers, we benchmarked thousands of context-specific models using well-established algorithms for the integration of omics data into the generic human metabolic model Recon3D. By analyzing the active reactions capable of carrying flux and their magnitude through flux balance analysis, we proved that the metabolic pattern of each cancer is unique and could act as a cancer metabolic fingerprint. Subsequently, we searched for proper feature selection methods to cluster the flux states characterizing each cancer. We employed PCA-based dimensionality reduction and a random forest learning algorithm to reveal reactions containing the most relevant information in order to effectively identify the most influential fluxes. Conclusively, we discovered different pathways that are probably the main sources for metabolic heterogeneity in cancers. We designed the GEMbench website to interactively present the data, methods, and analysis results.

1 March 2012 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
Amir Ali HamidiehAmir Ali Hamidieh
Amir Ali Hamidieh
MKMona Kargar
Mona Kargar
MJMohammad Jahani
Mohammad Jahani
KAKamran Alimoghaddam
Kamran Alimoghaddam
BBBabak Bahar
Babak Bahar
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
The most widely accepted conditioning regimen to allogeneic hematopoietic stem cell transplantation consists of total body irradiation, especially in patients affected by acute lymphoblastic leukemia (ALL). In this retrospective study, we report our experience on hematopoietic stem cell transplantation in 44 pediatric patients with acute lymphoblastic leukemia using a non-radiation–based conditioning regimen (busulfan/cyclophosphamide). Median age at transplantation was 12.5 years (range, 4 to 14 y). 39 out of 44 patients received transplants in complete remission. At a median follow-up of 390 days, the probabilities of 3-year disease-free survival and overall survival were 50% and 68%, respectively. Disease status of hematopoietic stem cell transplantation was the only significant variable affecting the overall survival. Acute and chronic graft-versus-host disease occurred in 23 (64%) and 12(18%) patients, respectively. Relapse was significantly higher among patients transplanted in advanced disease status. The results of the study indicate that non-radiation–based preparative regimens can be used in pediatric patients with ALL. However, well-designed comparative trials are needed to better clarify the difference between radiation and non-radiation–based conditioning regimens in pediatric ALL.

22 May 2018 in Turkish Journal of Hematology
Verified
Journal Article
Open access
MAMajid Teremmahi Ardestani
Majid Teremmahi Ardestani
AKAhmad Kazemi
Ahmad Kazemi
BCBahram Chahardouli
Bahram Chahardouli
SMSaeed Mohammadi
Saeed Mohammadi
MNMohsen Nikbakht
Mohsen Nikbakht
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
This study aimed to evaluate DNMT3A exon 23 mutations and their prognostic impacts in the presence of NPM1 and FLT3 mutations in acute myeloid leukemia (AML) patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). This study comprised 128 adult AML patients referred to the Hematology-Oncology and Stem Cell Research Center of Shariati Hospital. NPM1 and FLT3-ITD mutations were detected by fragment analysis. For DNMT3A exon 23 mutation analysis, we used Sanger sequencing. Overall survival (OS) and relapse-free survival (RFS) curves were estimated by the Kaplan-Meier method and the log-rank test was used to calculate differences between groups. The prevalence of DNMT3A exon 23 mutations was 15.6% and hotspot region R882 mutations were prominent. RFS and OS were compared in patients with and without DNMT3A exon 23 mutations using univariate analysis and there was no significant difference between these groups of patients. On the contrary, the FLT3-ITD mutation significantly reduced the OS (p=0.009) and RFS (p=0.006) in AML patients after allogeneic HSCT. In the next step, patients with AML were divided into four groups regarding FLT3-ITD and DNMT3A mutations. Patients with DNMT3A R882mut/FLT3-ITDpos had the worst OS and RFS. These results indicate that DNMT3A mutations alone do not affect the clinical outcomes of AML patients undergoing allogeneic HSCT, but when accompanied by FLT3-ITD mutations, the OS was significantly reduced (5-year OS 0% for DNMT3A R882mut/FLT3-ITDpos patients vs. 62% DNMT3A R882wt/FLT3-ITDneg, p=0.025) and the relapse rate increased. It can be deduced that DNMT3A R882mut/FLT3-ITDpos is an unfavorable prognostic factor in AML patients even after allogeneic HSCT.